147 related articles for article (PubMed ID: 26165466)
1. Delayed Cell Cycle Progression in STHdh(Q111)/Hdh(Q111) Cells, a Cell Model for Huntington's Disease Mediated by microRNA-19a, microRNA-146a and microRNA-432.
Das E; Jana NR; Bhattacharyya NP
Microrna; 2015; 4(2):86-100. PubMed ID: 26165466
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells.
Das E; Jana NR; Bhattacharyya NP
Biochem Biophys Res Commun; 2013 Jul; 437(2):217-24. PubMed ID: 23796713
[TBL] [Abstract][Full Text] [Related]
3. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
4. Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease.
Ghose J; Sinha M; Das E; Jana NR; Bhattacharyya NP
PLoS One; 2011; 6(8):e23837. PubMed ID: 21887328
[TBL] [Abstract][Full Text] [Related]
5. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.
Sinha M; Ghose J; Das E; Bhattarcharyya NP
Biochem Biophys Res Commun; 2010 Jun; 396(3):742-7. PubMed ID: 20451497
[TBL] [Abstract][Full Text] [Related]
6. Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.
Xifró X; Anglada-Huguet M; Rué L; Saavedra A; Pérez-Navarro E; Alberch J
Mol Neurodegener; 2011 Oct; 6():74. PubMed ID: 22041125
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line.
Kong PJ; Kil MO; Lee H; Kim SS; Johnson GV; Chun W
Neurol Res; 2009 Feb; 31(1):77-83. PubMed ID: 18691453
[TBL] [Abstract][Full Text] [Related]
8. Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease.
Anglada-Huguet M; Giralt A; Perez-Navarro E; Alberch J; Xifró X
J Neurochem; 2012 May; 121(4):639-48. PubMed ID: 22372926
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.
Ribeiro FM; Paquet M; Ferreira LT; Cregan T; Swan P; Cregan SP; Ferguson SS
J Neurosci; 2010 Jan; 30(1):316-24. PubMed ID: 20053912
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice.
Frederick NM; Bertho J; Patel KK; Petr GT; Bakradze E; Smith SB; Rosenberg PA
Neurochem Int; 2014 Oct; 76():59-69. PubMed ID: 25004085
[TBL] [Abstract][Full Text] [Related]
11. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
12. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease.
Molero AE; Gokhan S; Gonzalez S; Feig JL; Alexandre LC; Mehler MF
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21900-5. PubMed ID: 19955426
[TBL] [Abstract][Full Text] [Related]
13. Cognitive training modifies disease symptoms in a mouse model of Huntington's disease.
Yhnell E; Lelos MJ; Dunnett SB; Brooks SP
Exp Neurol; 2016 Aug; 282():19-26. PubMed ID: 27163546
[TBL] [Abstract][Full Text] [Related]
14. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
15. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
16. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin.
Jin YN; Yu YV; Gundemir S; Jo C; Cui M; Tieu K; Johnson GV
PLoS One; 2013; 8(3):e57932. PubMed ID: 23469253
[TBL] [Abstract][Full Text] [Related]
17. Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.
Chen GL; Ma Q; Goswami D; Shang J; Miller GM
J Cell Mol Med; 2017 Nov; 21(11):2974-2984. PubMed ID: 28524599
[TBL] [Abstract][Full Text] [Related]
18. Glutamate transporter expression and function in a striatal neuronal model of Huntington's disease.
Petr GT; Bakradze E; Frederick NM; Wang J; Armsen W; Aizenman E; Rosenberg PA
Neurochem Int; 2013 Jun; 62(7):973-81. PubMed ID: 23507328
[TBL] [Abstract][Full Text] [Related]
19. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
[TBL] [Abstract][Full Text] [Related]
20. Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington's disease knock-in striatal cell model STHdhQ111/Q111.
Ghatak S; Raha S
Biochem Biophys Res Commun; 2015 Apr; 459(3):509-14. PubMed ID: 25747711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
